Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668144 · ClinicalTrials.gov registry record · Phase 4
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 359
- Enrollment target
NCT04668144 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 359 participants.
The verdict
NCT04668144, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 359 participants
- Enrollment target
Study Summary
Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients undergoing coronary stenting. Although in this setting the potent oral P2Y12 inhibitor prasugrel is commonly utilized, there is very limited data on the optimal approach for switching between these therapies. The overarching aim of this investigation is to rule out a drug drug interaction (DDI) when cangrelor and prasugrel are concomitantly administered in patients undergoing coronary stenting.
Interventions
- DRUG Prasugrel
- DRUG Cangrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2023-05-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04668144
The ClinicalTrials.gov registry entry for NCT04668144 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prasugrel is the first listed.
NCT04668144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04668144 about?
NCT04668144 is a clinical study titled "Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI". Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients undergoing coronary stenting. Although in this setting the potent oral P2Y12 inhibitor prasugrel is commonly utiliz...
What is the current status of trial NCT04668144?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 359 participants. The study started on 2021-02-18. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT04668144?
The interventions under investigation include: Prasugrel (DRUG), Cangrelor (DRUG).
Who is sponsoring clinical trial NCT04668144?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.